I N T R O D U C T I O N
Atypical haemolytic and uraemic syndrome (aHUS) is a rare condition that rapidly compromises renal function, often in a matter of days. Although the majority of patients affected by aHUS have a genetic mutation in the alternate complement pathway [1, 2] , most cases are sporadic (mutation unknown at the first flare), thus important decisions must be made in the absence of information regarding exact mechanisms of endothelial injury. In order to take appropriate action, four issues should be considered immediately (see Figure 1 ): (i) the patient's background; (ii) the cause of the flare; (iii) the symptoms, particularly hypertension and (iv) whether and how the complement cascade should be stopped, and for how long.
T H E P A T I E N T
In two recent, relatively large European series of aHUS, the prevalence of genetic mutations in the alternate complement pathway ranged from 50 to 70% [1, 2] . This high number might still underestimate the real contribution of genetics because it fails to include genetic variants of unknown significance or mutations in biological pathways with the complement cascade. It is therefore imperative to ascertain even a remote familial history of renal disease, a need for dialysis or transplantation. Likewise, consanguinity should be questioned [3] .
It is important to have no preconceptions regarding the aetiology of a flare. To our knowledge there are no data regarding the prevalence and mechanisms of aHUS in low-income countries. A history of chronic hypertension, combined with poor compliance with anti-hypertensive drugs, may adversely point towards a malignant hypertension that, phenotypically, looks like aHUS: severe hypertension and proteinuria, mild to moderate features of thrombotic microangiopathy (TMA) and rapid deterioration of renal function are typical features of both syndromes [4] . Given the extremely poor renal prognosis of aHUS in the absence of a specific treatment, disregarding the genetic causes of aHUS for social or ethnical reasons is potentially prejudicial to the patient.
Lastly, pre-existing conditions must be considered. A woman carrying a mutation in the alternate complement pathway is at risk of an aHUS flare [5, 6] in the 4 months postpartum of an often uneventful pregnancy. In the transplantation setting, calcineurin inhibitors (CNIs) are known to cause TMA lesions [7] , occasionally with full TMA syndrome, including peripheral features of thrombopenia and haemolytic anaemia [8] . However, cases have been reported in the absence of exposure to CNIs [9] , and ischaemia-reperfusion injury or ABO incompatibility between donor and recipient (where the renal endothelium is at risk) may be the explanation [10] . In one series of kidney recipients developing TMA posttransplant, the proportion of genetic mutations was as high as 29% and was observed to affect patients with end-stage renal disease (ESRD) of an origin other than aHUS [11] . Whether TMA requires a double hit, such as CNI intoxication, plus an allo-immune response directed at endothelial cells has never been assessed. Finally, TMA features may be observed in diffuse cancers where the prognosis is extremely unfavourable [12] .
T H E F L A R E
Flares of aHUS may occur during or within a few weeks of a trigger, which is frequently one of the following: an infectious episode, pregnancy or drug exposure [13] . In patients with a documented aHUS-associated genetic mutation, a viral episode or a bacterial infection not necessarily involving pathogens with a known endothelial tropism can act as a trigger [14] [15] [16] . For poorly understood reasons, pregnancy-related flares of aHUS typically occur post-partum, within 4 months of delivery [5] . Pregnancy does not influence the vital or renal prognoses of the flare [6] . Notably, a genetic mutation in the alternate pathway is insufficient to drive a flare of aHUS in a post-partum woman. Therefore a woman with a family history of aHUS and in whom a mutation would have been found in the absence of disease should not, in our opinion, receive negative counseling regarding the possibility of pregnancy. She must be monitored closely for evidence of TMA during the first 4 months post-partum, but there is no evidence that she should be treated pre-emptively with blockade of the final phase of complement.
Surprisingly, pregnancy might predispose to aHUS flares through mechanisms other than those driven by genetic mutations in the alternate complement pathway. The fact that haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, one form of TMA, complicates 20% of cases of preeclampsia probably reflects liver susceptibility to placental antiangiogenic factors (at least to sFlt1 and sEng, acting synergistically [17] ). Indeed, despite the fact that acute kidney injury (AKI) frequently accompanies HELLP syndrome, features of TMA are rarely seen in renal biopsy; acute tubular necrosis (ATN) is the usual feature [18, 19] . Nevertheless, there are complex cases of aHUS where pre-eclampsia serves as a first 'hit' and post-partum haemorrhage or use of a pro-coagulant/antifibrinolytic drug serves as a second (8% of cases of postpartum AKI in our field). Here, renal features of TMA may be present and genetic mutations absent, and exact management of these women is unclear. Conversely, examining the recent use of drugs is especially important [20] . For example, gemcitabine or mitomycin C are unequivocally associated with flares of aHUS in some patients, but for other drugs causality is difficult to ascertain. Non-steroidal anti-inflammatory drugs (so frequently used over the counter that it is impossible to assess their contribution), CNIs, quinine [21] (even taken as tonic water [22] ) and others have been reported as causing flares. Here there is no firm evidence that the classic therapeutic approach (plasma exchange if ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity is unknown, followed by eculizumab) is appropriate. Time alone is probably better associated with endothelial healing.
T H E S Y M P T O M S
Hypertension is systematically observed during an aHUS flare and, as explained above, may be so marked that a diagnosis of malignant hypertension is contemplated at the expense of identifying genetic causes of aHUS. This is extremely important since a genetically driven flare may resolve by rigorous blood pressure control, highlighting the aggravating role played by endothelial cells subjected to a high regimen of pressure ( Figure 1B shows the case of a young patient with a genetic mutation in the gene encoding complement factor H, whose peripheral TMA features fully resolved by controlling blood pressure alone). Recently, two studies exploring the genetics of patients with malignant hypertension showed seemingly contradictory results. In an American FIGURE 1: (A) Eight points to consider in order to protect the kidneys during a flare of aHUS. The history and the family history of the patient may help to distinguish between a toxic cause and a genetic cause of aHUS and decide whether eculizumab is urgently required or not (toxic causes only imply stopping the intake of the toxic substance). A low C3 antigen is regularly observed in the case of a defect in the alternate complement pathway. In the absence of any other indication, eculizumab should be started as soon as ADAMTS-13 activity is known to be >5%. Non-specific measures include hydration and control of blood pressure with the priority use of angiotensin-converting enzyme inhibitors or angiotensin 2 receptor antagonists. (B) Dynamics of TMA features in a young patient with malignant hypertension and aHUS. C3 antigen and factor H were low (0.55 g/L and 35% of control serum, respectively) due to a p.Cys673Arg mutation in CFH. Hb, haemoglobin; LDL, low-density lipoprotein.
aHUS effects on kidneys cohort of 100 patients whose kidney biopsies revealed the typical histological pattern of malignant hypertension (i.e. arteriolar acute lesions but no intraglomerular thrombi), there was zero mutation in the alternate complement pathway [23] . However, another study in The Netherlands, including only nine patients with 'hypertension-related' TMA, found six mutations, with a similar number (6/9) showing glomerular fibrin deposits; all six progressed to ESRD [24] . Although the indication for a renal biopsy is debatable in patients with malignant hypertension, it could be useful to measure the specificity of intraglomerular fibrin as a lesion of aHUS, thus avoiding delay in the administration of a complement blocking agent.
Importantly, a dual mechanism accounts for the renal failure observed during an aHUS flare: first is, of course, glomerular and arteriolar thrombi and second is ATN, since the vasa recta that provide oxygen to the tubular epithelium are downstream of the glomerular capillary flow. At present there is no specific treatment to attenuate the lesions or accelerate repair of what is theoretically reversible. It is mandatory that adequate hydration be maintained, particularly given diarrhoea is a frequent accompanying symptom of aHUS [1] . This approach has proved effective in typical HUS [25] .
T H E R A P E U T I C I N T E R V E N T I O N S
Non-specific measures essentially aim at blood pressure control and replenishing folic acid reserves. Despite AKI, angiotensinconverting enzyme inhibitors and angiotensin 2 receptor antagonists are drugs of first choice since renal localization of thrombotic microangiopathy is a source of increased renin secretion by ischaemic glomeruli. No clinical trial supports this approach, insofar as we are aware.
Specific intervention consists of blockade of the complement alternate pathway, the earlier the better [26] . Renal prognosis depends on the time spent without the appropriate drug, as shown in kidney recipients experiencing a relapse [27] . In the absence of a likely cause, it is reasonable to use plasma because it is currently the only source of ADAMTS-13 and-if TMA is due to TTP and not aHUS-it is lifesaving [28] . Because of renal failure and to prevent fluid overload, plasma exchange is safer than plasma alone [29] . As soon as testing for ADAMTS-13 is available (within a week in high-income countries), and if activity is >5%, then the diagnosis of aHUS is straightforward and eculizumab can be started. Current consensus is to ensure blockade of the complement pathway for a minimum of 1 year. The majority of patients without a genetic mutation known to cause aHUS will not relapse during follow-up [30] , which is why, considering the economic and personal constraints associated with this regimen, the decision to stop the drug should be (carefully) considered.
C O N C L U S I O N S
AKI remains the main challenge in patients experiencing a flare of aHUS. The alternate pathway of complement is causally involved in endothelial necrosis in the majority of patients, which is why complement blockade must be started as early as possible. Nonetheless, non-genetic factors contribute to renal failure and both the patient's background and the trigger of the flare must be carefully investigated. It is essential to control blood pressure and ensure adequate hydration.
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